RemeGenix, Inc
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
RemeGenix, Inc - overview
Established
2006
Location
Bethesda, MD, US
Primary Industry
Biotechnology
About
Based in Maryland, US, and founded in 2006 by co-founder J. Kelly Ganjei, RemeGenix, Inc. is developing innovative therapeutic and platform technologies for alzheimer's disease and other dementias. RemeGenix's flagship product, MoBA (Modulator of Beta Secretase Processing of Amyloid Precursor Protein), is designed to modulate APP processing, which is crucial in the pathogenesis of AD.
Additionally, the company’s NoMAD (novel models for alzheimer’s disease) offers a biological alternative that mimics human dementia, resulting in increased amyloid precursor protein (APP) processing, reduced cognitive function, and recovery of cognitive function.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Healthcare IT
Website
www.remegenix.com/
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.